GLP-1 (1-37) (human, rat, mouse, bovine) (trifluoroacetate salt)
(Synonyms: 胰高血糖素样肽-1（GLP-1）,Glucagon-like Peptide-1) 目录号 : GC43761An incretin hormone
Cas No.:87805-34-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
|
Cell experiment: |
HEK293 cells (5×104) are seeded in a 96-well plate and transiently cotransfected with the GLP-1R plasmid and the CRE-luciferase reporter plasmid. After a 48 h transfection, different concentrations of GLP-1(1–37) or GLP-1(7–37) are added, and the cells are incubated for 5 h. The cells are harvested for a luciferase assay using a luciferase assay[1]. |
|
Animal experiment: |
Mice[1]The normal KM mice are fasted for 16 h before the administration (i.p.) of GLP-1 and glucose. GLP-1(1-37) (25 nmol/kg) with or without exendin(9-39) (250 nmol/kg) is given in combination with glucose (4 g/kg). GLP-1(7-37) (25 nmol/kg) with or without exendin(9-39) (250 nmol/kg) is also administrated in combination with glucose (4 g/kg). The control group is treated with saline (NaCl, 9 g/l) and glucose (4 g/kg). The IPGTT is carried out at 0, 15, 30 and 60 min after glucose and protein administration, and the blood glucose levels are measured as described above[1]. |
|
References: [1]. Zhao L, et al. Glucagon-like peptide-1(1-37) can enhance blood glucose homeostasis in mice. Regul Pept. 2012 Oct 10;178(1-3):1-5. |
|
Glucagon-like peptide-1 (GLP-1) (1-37) is a 37-residue incretin hormone that is cleaved in vivo into active truncated forms.[1] GLP-1 (1-37) decreases plasma glucose level in high-fat-fed mice when administered at 25 nmol/kg but does not affect plasma insulin level.[2] Pretreament with GLP-1 (1-37) (24 nmol/kg) prevents blood glucose increases in fasted and glucose challenged mice with diabetes induced by streptozotocin.[3] It inhibits polyphagia and polydipsia in STZ-induced diabetic mice 10 and 20 days, respectively, following initiation of GLP-1 (1-37) administration at a dose of 24 nmol/kg. Pretreament with GLP-1 (1-37) (24 nmol/kg) also inhibits loss of pancreatic islets and global and pancreatic oxidative stress in mice with STZ-induced diabetes.
Reference:
[1]. Baggio, L.L., and Drucker, D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology 132(6), 2131-2157 (2007).
[2]. Lennox, R., Porter, D.W., Flatt, P.R., et al. (Val8)GLP-1-Glu-PAL: A GLP-1 agonist that improves hippocampal neurogenesis, glucose homeostasis, and β-cell function in high-fat-fed mice. ChemMedChem 8(4), 595-602 (2013).
[3]. Wu, Y.-L., Huang, J., Liu, J., et al. Protective effect of recombinant human glucagon-like peptide-1 (rhGLP-1) pretreatment in STZ-induced diabetic mice. J. Pept. Sci. 17(7), 499-504 (2011).
| Cas No. | 87805-34-3 | SDF | |
| 别名 | 胰高血糖素样肽-1（GLP-1）,Glucagon-like Peptide-1 | ||
| 化学名 | glucagon-like peptide I (human, rat, mouse, bovine), trifluoroacetate salt | ||
| Canonical SMILES | [H]N[C@H](C(N[C@H](C(N[C@@H](CCC(O)=O)C(N[C@H](C(N[C@@H](CCC(O)=O)C(N[C@@H](CCCNC(N)=N)C(N[C@H](C(N[C@H](C(N[C@@H](CCC(O)=O)C(NCC(N[C@]([C@@H](C)O)([H])C(N[C@H](C(N[C@]([C@@H](C)O)([H])C(N[C@@H](CO)C(N[C@H](C(N[C@@H](C(C)C)C(N[C@@H](CO)C(N[C@@H](CO)C(N[C@ | ||
| 分子式 | C186H275N51O59 • XCF3COOH | 分子量 | 4169.5 |
| 溶解度 | 1 mg/ml in water | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.2398 mL | 1.1992 mL | 2.3984 mL |
| 5 mM | 0.048 mL | 0.2398 mL | 0.4797 mL |
| 10 mM | 0.024 mL | 0.1199 mL | 0.2398 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。